Results 81 to 90 of about 36,148 (255)

The Spectrum of Abnormal Tongue Movements: Review of Phenomenology, Etiology, and Differential Diagnosis

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Classifying abnormal tongue movements is challenging due to their varied presentations and limited visibility compared to other body parts. Accurate identification of the phenomenology guides physical examination and can point to specific diagnoses.
Nathaniel Bendahan, Seyed‐Mohammad Fereshtehnejad, Christos Ganos, Emily Swinkin, Anthony E. Lang   +4 more
wiley   +1 more source

Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis [PDF]

, 2022
Sven Jarius, Lars Komorowski, Jens Regula, Jürgen Haas, Stefanie Brakopp, Brigitte Wildemann   +5 more
openalex   +1 more source

Human Cyclophilins—An Emerging Class of Drug Targets

Medicinal Research Reviews, EarlyView.
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova, Hana Navratilova, Kamil Musilek, Ondrej Benek   +3 more
wiley   +1 more source

Acute neuronal cell death and neuroinflammation per se do not trigger secondary autoimmune encephalitis in mice

Scientific Reports
Patients with virus encephalitis, such as herpes simplex encephalitis and Japanese encephalitis frequently relapse with autoimmune encephalitides associated with neural autoantibodies.
Justus Wilke, Antonios Ntolkeras, Vinicius Daguano Gastaldi, Kathrin Borowski, Bianca Teegen, Winfried Stöcker, Fred Lühder, Klaus-Armin Nave, Hannelore Ehrenreich   +8 more
doaj   +1 more source

Rapid recovery after intrathecal dexamethasone in FIRES

Epileptic Disorders, EarlyView.
João Filipe Nico, Ana Rita Fradique, Catarina Teixeira, Rita Moinho, Mariana Leitão Marques, Constança Santos, Joana Afonso Ribeiro, Filipe Palavra, Cristina Pereira   +8 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Rare autoimmune encephalitis presenting as fluid-attenuated inversion recovery-hyperintense lesions in anti-Myelin oligodendrocyte glycoprotein-associated encephalitis and seizures accompanied with anti-IgLON5 antibody [PDF]

, 2022
Wanyao Li, Wei Du, Yuhan Jiang, Yangyingqiu Liu, Na Liu, Yanwei Miao, Zhe Wang, Ying Wang   +7 more
openalex   +1 more source

A Transcriptomic Analysis of Cancer‐Stromal Interactome in Lung Cancer Xenograft Models

Cancer Science, EarlyView.
We conducted a comprehensive analysis of the lung cancer interactome to identify key ligand–receptor pairs involved in the aggressiveness of lung adenocarcinoma. Tumor necrosis factor superfamily member 12 and its receptor tumor necrosis factor receptor superfamily member 12A signaling axis may be potential candidates for therapeutic intervention for ...
Yuriko Takayama‐Isagawa, Daisuke Komura, Takayuki Isagawa, Yusuke Amano, Atsushi Kihara, Tamaki Miura, Taichiro Yoshimoto, Hiroyoshi Tsubochi, Kazutaka Fujita, Koichi Hagiwara, Makoto Maemondo, Tetsuo Ushiku, Shumpei Ishikawa, Noriyoshi Fukushima, Kentaro Inamura, Daisuke Matsubara, Toshiro Niki   +16 more
wiley   +1 more source

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Toyofumi F. Chen‐Yoshikawa, Yasushi Goto, Wataru Nishio, Shizuka Nakagawa, Morihiko Hayashi, Hirotsugu Kenmotsu   +9 more
wiley   +1 more source

Case Report: Refractory Hypotension of GABA B Receptor Autoimmune Encephalitis [PDF]

, 2020
Kong Hanxin, Xiaomin Wang, Ying Hao, Shuihong Zheng   +3 more
openalex   +1 more source